Abbott Laboratories (NYSE:ABT) Trading Down 0.4%

Abbott Laboratories (NYSE:ABT - Get Free Report)'s share price traded down 0.4% during trading on Tuesday . The company traded as low as $111.20 and last traded at $111.40. 624,561 shares traded hands during trading, a decline of 90% from the average session volume of 5,983,688 shares. The stock had previously closed at $111.90.

Analyst Ratings Changes

ABT has been the subject of several research reports. Raymond James restated a "buy" rating and set a $124.00 price objective on shares of Abbott Laboratories in a research report on Wednesday, April 24th. Barclays raised their price objective on shares of Abbott Laboratories from $140.00 to $143.00 and gave the stock an "overweight" rating in a research report on Monday, July 29th. Royal Bank of Canada restated an "outperform" rating and set a $125.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, June 4th. The Goldman Sachs Group initiated coverage on shares of Abbott Laboratories in a research report on Thursday, May 30th. They issued a "buy" rating and a $121.00 price target for the company. Finally, Evercore ISI cut their target price on Abbott Laboratories from $125.00 to $120.00 and set an "outperform" rating for the company in a research note on Tuesday, July 2nd. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $121.00.

Abbott Laboratories Trading Down 1.0 %

The firm's 50 day moving average price is $105.66 and its 200-day moving average price is $108.70. The stock has a market cap of $192.70 billion, a P/E ratio of 34.51, a P/E/G ratio of 2.74 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.68 and a quick ratio of 1.11.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 18th. The healthcare product maker reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.04. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The firm had revenue of $10.38 billion during the quarter, compared to analysts' expectations of $10.37 billion. During the same period in the prior year, the company posted $1.08 earnings per share. The company's revenue for the quarter was up 4.0% compared to the same quarter last year. As a group, equities research analysts forecast that Abbott Laboratories will post 4.66 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 15th. Investors of record on Monday, July 15th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Monday, July 15th. This represents a $2.20 dividend on an annualized basis and a yield of 1.99%. Abbott Laboratories's payout ratio is 68.54%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC grew its position in shares of Abbott Laboratories by 28.4% in the 4th quarter. International Assets Investment Management LLC now owns 12,257 shares of the healthcare product maker's stock worth $1,349,000 after buying an additional 2,714 shares during the last quarter. Capital Investment Advisory Services LLC grew its position in shares of Abbott Laboratories by 11.5% during the fourth quarter. Capital Investment Advisory Services LLC now owns 16,748 shares of the healthcare product maker's stock worth $1,843,000 after buying an additional 1,724 shares in the last quarter. GUNN & Co INVESTMENT MANAGEMENT INC. purchased a new stake in Abbott Laboratories during the fourth quarter worth approximately $1,075,000. Jennison Associates LLC lifted its stake in Abbott Laboratories by 1.1% in the fourth quarter. Jennison Associates LLC now owns 400,107 shares of the healthcare product maker's stock valued at $44,040,000 after buying an additional 4,309 shares during the last quarter. Finally, Significant Wealth Partners LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $603,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.